SWTX Overview
Upcoming Projects (SWTX)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (SWTX)
-
A Second Look: Discussing the primary results from the KOMET Phase 3 trial (NCT04924608) presented at ASCO, evaluating Koselugo (selumetinib) in adults with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibroma.
Tickers: AZN, SWTX
Executed On: Jun 05, 2025 at 01:30 PM EDT -
Discussing the potential of Gomekli (Mirdametinib) as a treatment for neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN).
Ticker: SWTX
Executed On: Apr 07, 2025 at 09:45 AM EDT -
A look at Abstract-8019: Blenrep + nirogacestat in r/r Multiple myeloma (DREAMM-5 STUDY) - 2nd view
Tickers: SWTX, GSK
Executed On: May 25, 2022 at 01:00 PM EDT -
A look at Abstract-8019: Blenrep + nirogacestat in r/r Multiple myeloma (DREAMM-5 STUDY)
Tickers: SWTX, GSK
Executed On: May 20, 2022 at 02:00 PM EDT
Upcoming & Overdue Catalysts (SWTX)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (SWTX)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
